HEME Home Transfusion Program

Recruiting now · Not applicable

Conditions studied: Leukemia, Myeloma, Myelodysplastic Syndromes, Hematologic Malignancy, Hematologic Diseases, Lymphoma

In brief

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

Key facts

Study ID

NCT06487247

Run by

Dana-Farber Cancer Institute

People needed

700

Starts

2025-09-10

Expected to finish

2029-05-31

Last updated by the study team

2025-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.